Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 14, 2015, Pages 2521-2522

  Berretta, M ^a   Di Francia, R ^b,c   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Italian Association of Pharmacogenomics and Molecular Diagnostics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; TUMOR MARKER; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PATIENT SAFETY; PATIENT SELECTION; PREVALENCE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CATHETER ABLATION; LIVER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CATHETER ABLATION; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84942324213     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. KAN X, JING Y, WAN QY, PAN JC, HAN M, YANG Y, ZHU M, WANG Q, LIU KH. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2015; 19: 247-255.
2. DI BENEDETTO F, TARANTINO G, QUINTINI C, TIRELLI U, BERRETTA M. Hepatocellular carcinoma: beyond the boundaries of age. Anticancer Agents Med Chem 2013; 13: 1371-1377.
3. BERRETTA M, GARLASSI E, CACOPARDO B, CAPPELLANI A, GUARALDI G, COCCHI S, DE PAOLI P, LLESHI A, IZZI I, TORRESIN A, DI GANGI P, PIETRANGELO A, FERRARI M, BEARZ A, BERRETTA S, NASTI G, DI BENEDETTO F, BALESTRERI L, TIRELLI U, VENTURA P. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011; 16: 1258-1269.
4. NUNNARI G, BERRETTA M, PINZONE MR, DI ROSA M, BERRETTA S, CUNSOLO G, MALAGUARNERA M, COSENTINO S, DE PAOLI P, SCHNELL JM, CACOPARDO B. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16: 1257-1270.
5. URSINO S, GRECO C, CARTEI F, COLOSIMO C, STEFANELLI A, CACOPARDO B, BERRETTA M, FIORICA F. Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur Rev Med Pharmacol Sci 2012; 16: 1599-1604.
6. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, QUINTINI C, CODELUPPI M, TIRELLI U, GERUNDA GE. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006; 24: e26-7.
7. TAVIO M, GROSSI P, BACCARANI U, SCUDELLER L, PEA F, BERRETTA M, ADANI G, VIVARELLI M, RIVA A, TIRELLI U, BRESADOLA V, VIALE P, RISALITI A. HIV-infected patients and liver transplantation: who, when and why. Curr HIV Res 2011; 9: 120-127.
8. DI BENEDETTO F, TARANTINO G, ERCOLANI G, BACCARANI U, MONTALTI R, DE RUVO N, BERRETTA M, ADANI GL, ZANELLO M, TAVIO M, CAUTERO N, TIRELLI U, PINNA AD, GERUNDA GE, GUARALDI G. Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist 2013; 18: 592-599.
9. BERRETTA M, DI BENEDETTO F, DAL MASO L, CACOPARDO B, NASTI G, FACCHINI G, BEARZ A, SPINA M, GARLASSI E, DE RE V, FIORICA F, LLESHI A, TIRELLI U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24: 212-218.
10. BERRETTA M, DI FRANCIA R, TIRELLI U. The new oncologic challenges in the 3rd millennium WCRJ 2014; 1: e133